Abstract:Abstract Acquired apoptosis resistance plays an important role in acquired chemoresistance in cancer cells during chemotherapy. Based on our previous observations that acquired TNF-related apoptosis-inducing ligand (TRAIL)-resistance in lung cancer cells was associated with Akt-mediated stabilization of c-FLIP and Mcl-1, we further examined if the TRAIL-resistant cells also have acquired resistance to apoptosis induced by chemotherapeutics, such as cisplatin (CDDP) and adriamycin (Adr), and the mechanism underlying this resistance. By systematically delineating the signaling pathway for acquired apoptosis resistance using in vitro cell culture and in vivo xenografted tumor models, we determined that these TRAIL-resistant cells also have acquired resistance to apoptosis induced by chemotherapeutics such as cisplatin (CDDP) and adriamycin (Adr). We further found that COX-2 is dramatically overexpressed in cells with acquired apoptosis resistance. COX-2 appears to be a crucial mediator in acquired apoptosis resistance because suppressing COX-2 activity with chemical inhibitors or reducing COX-2 protein expression level with COX-2 siRNA dramatically alleviated resistance to therapeutic-induced apoptosis both in vitro and in vivo. Inhibiting Akt markedly reduced COX-2 expression, suggesting COX-2 is a downstream effector mediating apoptosis resistance of this cell survival kinase. Furthermore, the expression of Mcl-1 but not c-FLIP was significantly reduced when COX-2 was suppressed and knockdown of Mcl-1 substantially sensitized the cells to CDDP- or Adr-induced apoptosis. Our results establish a novel pathway that consists of Akt, COX-2, and Mcl-1 for acquired apoptosis resistance, which could be a molecular target for circumventing acquired chemoresistance in lung cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2568.

Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.

Molecular Mechanisms of Resistance to TRAIL-induced Apoptosis in Tumor

Adenovirus-mediated Inhibitor Kappab Gene Transfer Improves the Chemosensitivity to Anticancer Drugs in Human Lung Cancer in Vitro and in Vivo.

Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy

The Accomplices of NF-κB Lead to Radioresistance.

Apatinib-induced NF-κB Inactivation Sensitizes Triple-Negative Breast Cancer Cells to Doxorubicin.

AdIκBα transfer reverses the chemoresistance to taxol by inducing apoptosis in nude mice with human non-small cell lung cancer

The Accomplices of NF-&#954;B Lead to Radioresistance

Digitoflavone Inhibits IκBα Kinase and Enhances Apoptosis Induced by TNFα Through Downregulation of Expression of Nuclear Factor Κb-Regulated Gene Products in Human Pancreatic Cancer Cells

Enhancement Of Chemotherapeutic Agent-Induced Apoptosis By Inhibition Of Nf-Kappa B Using Ursolic Acid

Blockage of Nf-Kappa B by Ikk Beta- or Rela-Sirna Rather Than the Nf-Kappa B Super-Suppressor I Kappa B Alpha Mutant Potentiates Adriamycin-Induced Cytotoxicity in Lung Cancer Cells

Control of the Senescence-Associated Secretory Phenotype by NF-κB Promotes Senescence and Enhances Chemosensitivity.

Modulating multidrug resistance to drug-based antitumor therapies through NF-κB signaling pathway: mechanisms and perspectives

Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers

NF-κB signaling in therapy resistance of breast cancer: Mechanisms, approaches, and challenges

Acquired Activation of the Akt/Cyclooxygenase-2/Mcl-1 Pathway Renders Lung Cancer Cells Resistant to Apoptosis

Abstract 2568: Acquired Apoptosis Resistance Mediated by Activation of the Akt/COX-2/Mcl-1 Pathway in Lung Cancer Cells

Controlling Cancer Cell Death Types to Optimize Anti-Tumor Immunity

TNF-α sensitizes chemotherapy and radiotherapy against breast cancer cells

Antagonizing CDK8 Sensitizes Colorectal Cancer to Radiation Through Potentiating the Transcription of E2f1 Target Gene Apaf1